We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

145 hedge funds and large institutions have $792M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 54 increasing their positions, 43 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 43

21% more call options, than puts

Call options by funds: $264K | Put options by funds: $218K

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 15

1% less funds holding

Funds holding: 146145 (-1)

12% less capital invested

Capital invested by funds: $897M → $792M (-$104M)

Holders
145
Holders Change
-1
Holders Change %
-0.68%
% of All Funds
2.28%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
15
Increased
54
Reduced
43
Closed
15
Calls
$264K
Puts
$218K
Net Calls
+$46K
Net Calls Change
-$84K
Name Holding Trade Value Shares
Change
Change in
Stake
DM
1
Deerfield Management
New York
$94.4M +$21.3M +1,488,388 +29%
BlackRock
2
BlackRock
New York
$77M -$1.1M -76,989 -1%
RG
3
Redmile Group
California
$68.7M -$10.1M -703,539 -13%
AC
4
Armistice Capital
New York
$64.2M +$6.58M +460,000 +11%
Vanguard Group
5
Vanguard Group
Pennsylvania
$61.8M -$3.13M -218,820 -5%
B
6
Braidwell
Connecticut
$51.3M +$5.8M +405,068 +12%
State Street
7
State Street
Massachusetts
$44.6M -$2.18M -152,655 -5%
Goldman Sachs
8
Goldman Sachs
New York
$29.9M -$13.4M -933,879 -31%
PCH
9
Polar Capital Holdings
United Kingdom
$24.6M
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$19.8M +$525K +36,718 +3%
Morgan Stanley
11
Morgan Stanley
New York
$19.3M +$6.25M +436,913 +47%
N
12
Nuveen
North Carolina
$19.1M +$480K +33,549 +3%
NLVP
13
New Leaf Venture Partners
New York
$17M
Geode Capital Management
14
Geode Capital Management
Massachusetts
$15.6M +$620K +43,301 +4%
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
$12M -$327K -22,862 -3%
Assenagon Asset Management
16
Assenagon Asset Management
Luxembourg
$11.9M
Point72 Asset Management
17
Point72 Asset Management
Connecticut
$8.71M +$7.8M +544,995 +737%
PHP
18
Parkman Healthcare Partners
Connecticut
$8.07M +$1.17M +81,467 +17%
ECM
19
ExodusPoint Capital Management
New York
$7.61M +$1.51M +105,646 +24%
Northern Trust
20
Northern Trust
Illinois
$7.29M +$173K +12,094 +2%
Charles Schwab
21
Charles Schwab
California
$6.95M +$524K +36,615 +8%
UBS AM
22
UBS AM
Illinois
$6.43M
JFG
23
Jefferies Financial Group
New York
$6.06M -$10.7M -744,850 -63%
D.E. Shaw & Co
24
D.E. Shaw & Co
New York
$5.38M -$5.85M -408,974 -52%
FLSM
25
Frazier Life Sciences Management
California
$5.21M +$5.29M +370,000 New

DCPH Hedge Fund Activity: Q2 2023 in Review

145 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q2 2023, worth a combined $792M — down 12% from $897M a quarter earlier.

Fund positioning in DCPH was balanced in Q2 2023: 15 funds opened new positions, 15 closed out, 54 added to existing stakes and 43 trimmed.

The largest buyer was Deerfield Management, adding an estimated $21.3M. The largest seller was Deep Track Capital, exiting entirely with an estimated $21.1M sold.

  • 145 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q2 2023, down from 146 in Q1 2023.
  • Funds reported $792M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q2 2023, down 12% quarter-over-quarter.
  • 15 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q2 2023 and 15 closed out, a net change of 0 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q2 2023 was Deerfield Management, an estimated $21.3M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q2 2023 was Deep Track Capital, an estimated $21.1M sold.

Based on aggregated 13F filings for Q2 2023.